Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Sell
50
ARWR Quote, Financials, Valuation and Earnings
Last price:
$68.58
Seasonality move
:
40.49%
Day range:
$65.40 - $71.50
52-week range:
$9.57 - $71.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
11.04x
P/B ratio:
19.99x
Volume:
5.1M
Avg. volume:
2.6M
1-year change:
190.55%
Market cap:
$9.3B
Revenue:
$829.4M
EPS (TTM):
-$0.07
Analysts' Opinion
-
Consensus RatingArrowhead Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $57.67, Arrowhead Pharmaceuticals, Inc. has an estimated downside of -15.94% from its current price of $68.60.
-
Price Target UpsideAccording to analysts, the highest upside price target is $85.00 representing -100% upside increase from its current price of $68.60.
Fair Value
-
According to the consensus of 11 analysts, Arrowhead Pharmaceuticals, Inc. has -15.94% downside to fair value with a price target of $57.67 per share.
ARWR vs. S&P 500
-
Over the past 5 trading days, Arrowhead Pharmaceuticals, Inc. has overperformed the S&P 500 by 22.01% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Arrowhead Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Arrowhead Pharmaceuticals, Inc. revenues have been falling on a year-over-year basis for 8 quarters in a row. In the most recent quarter Arrowhead Pharmaceuticals, Inc. reported revenues of $256.5M.
Earnings Growth
-
Arrowhead Pharmaceuticals, Inc. has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Arrowhead Pharmaceuticals, Inc. reported earnings per share of -$0.18.
Enterprise value:
9.2B
EV / Invested capital:
7.41x
Price / LTM sales:
11.04x
EV / EBIT:
93.22x
EV / Revenue:
11.05x
PEG ratio (5yr expected):
-0.03x
EV / Free cash flow:
58.44x
Price / Operating cash flow:
58.38x
Enterprise value / EBITDA:
74.98x
Gross Profit (TTM):
$805.5M
Return On Assets:
2.3%
Net Income Margin (TTM):
3.63%
Return On Equity:
7.7%
Return On Invested Capital:
2.57%
Operating Margin:
17.2%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $240.7M | $3.6M | $829.4M | -- | $256.5M | |
| Gross Profit | $228.2M | -$15M | $805.5M | -$5M | $250.1M | |
| Operating Income | -$205M | -$601.1M | $98.3M | -$162.2M | $44.1M | |
| EBITDA | -$192.5M | -$582.5M | $122.3M | -$157.2M | $50.5M | |
| Diluted EPS | -$1.92 | -$5.00 | -$0.07 | -$1.37 | -$0.18 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $384.6M | $405.3M | $419.5M | $695.5M | $950.6M | |
| Total Assets | $710.1M | $691.9M | $765.6M | $1.1B | $1.5B | |
| Current Liabilities | $146.5M | $138.9M | $105.5M | $103.2M | $195.5M | |
| Total Liabilities | $301.3M | $273.6M | $478.4M | $948.7M | $947M | |
| Total Equity | $408.8M | $418.3M | $287.2M | $191.1M | $503.4M | |
| Total Debt | $23.3M | $78.8M | $372.9M | $845.6M | $726.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$153.9M | -$462.9M | $179.6M | -$137.2M | $20.5M | |
| Cash From Investing | -$96.2M | -$420.1M | -$129.3M | -$222.9M | $72.6M | |
| Cash From Financing | $253.1M | $870.5M | $74M | $389.1M | $3.7M | |
| Free Cash Flow | -$330.6M | -$604.3M | $156.9M | -$161.5M | $13M | |
ARWR
Sector
Market Cap
$9.3B
$28.5M
Price % of 52-Week High
95.94%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-6.97%
-1.33%
1-Year Price Total Return
190.56%
-20.32%
Beta (5-Year)
1.279
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$60.55
200-day SMA
Buy
Level
$23.80
Bollinger Bands (100)
Buy
Level
20.01 - 44.73
Chaikin Money Flow
Sell
Level
-38.2M
20-day SMA
Buy
Level
$48.94
Relative Strength Index (RSI14)
Buy
Level
75.92
ADX Line
Buy
Level
43.62
Williams %R
Sell
Level
-8.4204
50-day SMA
Buy
Level
$42.23
MACD (12, 26)
Buy
Level
6.94
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Neutral
Level
184.5M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.8151)
Sell
CA Score
(Annual)
Level (-1.0124)
Buy
Beneish M-Score
(Annual)
Level (-17.9468)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-10.5715)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
Stock Forecast FAQ
In the current month, ARWR has received 7 Buy ratings 4 Hold ratings, and 0 Sell ratings. The ARWR average analyst price target in the past 3 months is $57.67.
-
Where Will Arrowhead Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Arrowhead Pharmaceuticals, Inc. share price will drop to $57.67 per share over the next 12 months.
-
What Do Analysts Say About Arrowhead Pharmaceuticals, Inc.?
Analysts are divided on their view about Arrowhead Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Arrowhead Pharmaceuticals, Inc. is a Sell and believe this share price will rise from its current level to $17.00.
-
What Is Arrowhead Pharmaceuticals, Inc.'s Price Target?
The price target for Arrowhead Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $57.67 according to 11 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is ARWR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Arrowhead Pharmaceuticals, Inc. is a Buy. 7 of 11 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ARWR?
You can purchase shares of Arrowhead Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Arrowhead Pharmaceuticals, Inc. shares.
-
What Is The Arrowhead Pharmaceuticals, Inc. Share Price Today?
Arrowhead Pharmaceuticals, Inc. was last trading at $68.58 per share. This represents the most recent stock quote for Arrowhead Pharmaceuticals, Inc.. Yesterday, Arrowhead Pharmaceuticals, Inc. closed at $68.60 per share.
-
How To Buy Arrowhead Pharmaceuticals, Inc. Stock Online?
In order to purchase Arrowhead Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ARWR Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ARWR
Sector
P/E ratio
--
23.75x
PEG ratio
-0.03x
-0.01x
P/B ratio
19.99x
1.83x
Price / LTM sales
11.04x
1.60x
Growth Metrics
ARWR
Sector
Revenue growth
-29.6%
4.85%
Earnings growth
87.24%
11.11%
Revenue (5-year growth)
56.63%
6.45%
Earnings forecast
-$0.16
-$0.20
Profitability
ARWR
Sector
Profitability FY 2025
$805.5M
$3.6M
Return on invested capital
2.57%
-30.98%
Return on assets
2.3%
-27.62%
Return on equity
7.7%
-36.69%
Earnings Date
Last Earnings Date
Nov
25
Next Earnings Date
Feb
9
Estimated Next Earnings Date
Feb
24
Balance Sheet
ARWR
Sector
Total cash
$919.4M
$27.2M
Short term investments
$578.3M
$25.7M
Total assets
$1.5B
$79.7M
Long term debt
$726.4M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
67
GPCR alert for Dec 9
Structure Therapeutics, Inc. [GPCR] is up 102.52% over the past day.
Buy
62
SMX alert for Dec 9
SMX (Security Matters) Plc [SMX] is down 59.64% over the past day.
Buy
90
KYMR alert for Dec 9
Kymera Therapeutics, Inc. [KYMR] is up 41.67% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
